{"id":198,"date":"2011-10-27T12:06:06","date_gmt":"2011-10-27T12:06:06","guid":{"rendered":"https:\/\/blogs.nature.com\/spoonful\/2011\/10\/new-patent-sharing-scheme-targets-neglected-diseases-but-with-a-possible-catch.html"},"modified":"2011-10-27T12:06:06","modified_gmt":"2011-10-27T12:06:06","slug":"new_patent_sharing_scheme_targ","status":"publish","type":"post","link":"https:\/\/blogs.nature.com\/spoonful\/2011\/10\/new_patent_sharing_scheme_targ.html","title":{"rendered":"New patent sharing scheme targets neglected diseases, but with a possible catch"},"content":{"rendered":"<p>Diseases that disproportionally afflict the world\u2019s poor provide few incentives for profit-seeking drug companies. In the past couple years, collaborative patent sharing schemes have popped up to remedy this by helping drugmakers develop low-cost medicines for less developed nations. Last year, for example, <span class=\"caps\">UNITAID<\/span> launched the <a href=\"https:\/\/www.medicinespatentpool.org\/\">Medicines Patent Pool<\/a> (<span class=\"caps\">MPP<\/span>), which focuses on <span class=\"caps\">HIV<\/span> drugs.<\/p>\n<p>Yesterday, the <a href=\"https:\/\/www.wipo.int\/\">World Intellectual Property Organization<\/a> (<span class=\"caps\">WIPO<\/span>), a Geneva-based arm of the United Nations, <a href=\"https:\/\/www.wipo.int\/pressroom\/en\/articles\/2011\/article_0026.html\">unveiled<\/a> its <a href=\"https:\/\/www.wipo.int\/research\/en\/\">Re:Search database<\/a>, a new open-access resource aimed at tackling malaria, tuberculosis and neglected tropical diseases. The database was launched in partnership with the Washington, DC-based non-profit <a href=\"https:\/\/www.bvgh.org\/\"><span class=\"caps\">BIO<\/span> Ventures for Global Health<\/a> (<span class=\"caps\">BVGH<\/span>). Since 2009, <span class=\"caps\">BVGH<\/span> has administered the <a href=\"https:\/\/ntdpool.org\/\">Pool for Open Innovation against Neglected Tropical Diseases<\/a> formed by the British drug giant GlaxoSmithKline.<\/p>\n<p>But organizers hope that Re:Search will grow to ultimately supplant that database. Like GlaxoSmithKline\u2019s effort, WIPO\u2019s resource compiles intellectual property beyond patents, including assets related to many steps in the drug development process, such as research tools, manufacturing technology, as well as both experimental and marketed compounds. However, it is far more extensive, as eight major pharmaceutical companies and a dozen non-profit research organizations from around the world have contributed. The database is available to all scientists and drugmakers free of charge as long as they agree that any therapies stemming from the information are sold at cost of production to the UN\u2019s list of the 48 least developed countries in the world.<\/p>\n<p><a href=\"https:\/\/gspp.berkeley.edu\/academics\/affiliates\/maurer.html\">Stephen Maurer<\/a>, who studies innovation and science policy at the University of California\u2013Berkeley School of Law, thinks that sharing non-patented proprietary information, previously held hostage by institutions, is the database\u2019s major contribution. \u201cThis is a good first step in terms of getting out of this problem that intellectual property does nothing for the developing world,\u201d he says.<\/p>\n<p>However, <a href=\"https:\/\/www.openrightsgroup.org\/people\/advisory#michelle_childs\">Michelle Childs<\/a>, director of policy and advocacy at M\u00e9decins Sans Fronti\u00e8res\u2019 <a href=\"https:\/\/www.msfaccess.org\/\">Campaign for Access to Essential Medicines<\/a> in Geneva, worries that by only making drugs available to the most impoverished nations, Re:Search \u2014 like other patent pools before it \u2014 could leave out people in middle-income countries who can\u2019t afford full-price meds (see <em><a href=\"https:\/\/www.nature.com\/nm\/journal\/v17\/n9\/full\/nm0911-1023.html\">Nat. Med.<\/em> <b>17<\/b>, 1023\u20131023, 2011<\/a>).<\/p>\n<p>\u201cRestricting access to the least developed countries is just ignoring where people with neglected tropical diseases live,\u201d Childs says. \u201cBy agreeing to licensing terms that have such an unacceptably limited geographical scope, the UN \u2014 a norm setting agency \u2014 is setting a bad precedent for future licensing arrangements.\u201d<\/p>\n<p>And without concrete targets, some experts worry whether the initiative will actually deliver on its stated goal of promoting the development of new drugs, vaccines and diagnostics. \u201cStatements of goodwill made in good faith are not good enough,\u201d says <span class=\"caps\">MPP<\/span> head <a href=\"https:\/\/www.medicinespatentpool.org\/WHO-WE-ARE2\/The-Team\">Ellen t\u2019 Hoen<\/a>. \u201cActual action needs to be put behind it.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Diseases that disproportionally afflict the world\u2019s poor provide few incentives for profit-seeking drug companies. In the past couple years, collaborative patent sharing schemes have popped up to remedy this by helping drugmakers develop low-cost medicines for less developed nations. Last year, for example, UNITAID launched the Medicines Patent Pool (MPP), which focuses on HIV drugs.&nbsp; <a href=\"https:\/\/blogs.nature.com\/spoonful\/2011\/10\/new_patent_sharing_scheme_targ.html#wpn-more-198\" class=\"more-link\">Read more<\/a> <a href=\"https:\/\/blogs.nature.com\/spoonful\/2011\/10\/new_patent_sharing_scheme_targ.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":128,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[9],"tags":[],"class_list":["post-198","post","type-post","status-publish","format-standard","hentry","category-odds-and-ends"],"_links":{"self":[{"href":"https:\/\/blogs.nature.com\/spoonful\/wp-json\/wp\/v2\/posts\/198","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.nature.com\/spoonful\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.nature.com\/spoonful\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.nature.com\/spoonful\/wp-json\/wp\/v2\/users\/128"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.nature.com\/spoonful\/wp-json\/wp\/v2\/comments?post=198"}],"version-history":[{"count":0,"href":"https:\/\/blogs.nature.com\/spoonful\/wp-json\/wp\/v2\/posts\/198\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.nature.com\/spoonful\/wp-json\/wp\/v2\/media?parent=198"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.nature.com\/spoonful\/wp-json\/wp\/v2\/categories?post=198"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.nature.com\/spoonful\/wp-json\/wp\/v2\/tags?post=198"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}